Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 12/03 07:01:46 am
417.775 DKK   -0.68%
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
AQ
12/01NOVO NORDISK A/S : ESG presentation ()
PU
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVO NORDISK : Credit Suisse gives a Buy rating

10/09/2020 | 12:14pm EST

In a research note published by Trung Huynh, Credit Suisse advises its customers to buy the stock. The target price is unchanged and still at DKK 470.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
CREDIT SUISSE GROUP AG 0.60% 11.595 Delayed Quote.-10.99%
NOVO NORDISK A/S -0.75% 417.8 Delayed Quote.8.79%
All news about NOVO NORDISK A/S
12/01NOVO NORDISK A/S : - Company announcements, trading in own shares
AQ
12/01NOVO NORDISK A/S : ESG presentation ()
PU
12/01NOVO NORDISK : Gets a Buy rating from JP Morgan
MD
11/30Weight-Loss Firm Noom Names First CFO
DJ
11/23NOVO NORDISK A/S : – Share repurchase programme
AQ
11/20India's Gland Pharma jumps 23% in market debut
RE
11/18NOVO NORDISK A/S : - Once-weekly semaglutide 2.0 mg demonstrates superior reduct..
AQ
11/18NOVO NORDISK A/S : Experts Urge Govt to Subsidise Cost of Diabetes Management, T..
AQ
11/17NOVO NORDISK A/S : Once-weekly semaglutide 2.0 mg demonstrates superior reductio..
AQ
11/16GILEAD SCIENCES : and Novo Nordisk Present New Data from Proof-of-Concept Trial ..
AQ
More news
Financials
Sales 2020 127 B 20 745 M 20 745 M
Net income 2020 42 174 M 6 867 M 6 867 M
Net cash 2020 8 472 M 1 379 M 1 379 M
P/E ratio 2020 23,2x
Yield 2020 2,14%
Capitalization 974 B 158 B 159 B
EV / Sales 2020 7,57x
EV / Sales 2021 7,11x
Nbr of Employees 44 326
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 439,69 DKK
Last Close Price 420,65 DKK
Spread / Highest target 29,6%
Spread / Average Target 4,53%
Spread / Lowest Target -31,1%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S8.79%158 090
JOHNSON & JOHNSON1.56%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.9.91%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033